GEN Exclusives

More »

GEN News Highlights

More »
Aug 24, 2007

Gene Logic Tasked with Repositioning Merck Serono Drugs

  • Gene Logic plans to research alternative development paths for several Merck Serono clinical candidates under a drug-repositioning agreement. All the candidates were discontinued or de-prioritized for reasons other than safety, according to the companies.

    Gene Logic will receive success-based milestones and royalties. If Gene Logic identifies a new therapeutic use for any compound, the company has the right to exclusively license the drug so long as Merck Serono opts out of development. Merck Serono then would be entitled to success-based milestone and royalty payments on these licensed candidates.

    Gene Logic has similar repositioning collaborations with Eli Lilly, Lundbeck, Abbott, Organon, Roche, and Pfizer.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Ebola Vaccines

When do you think an Ebola vaccine will be available for the general public?